In this issue of Circulation, the 3 year follow up of the PARTNER B trial provides us with a sobering final word on the natural history of severe aortic stenosis 1 . As described 50 years ago, severe aortic stenosis is a terminal illness of the elderly with a progression from symptoms to death over an approximately 3 year period 2, 3 . The current report of the 3 year follow up from the PARTNER B trial confirms this dismal natural history: among patients randomized to standard therapy in the initial trial and/or continued access study, 81% are dead after 3 years.
Transcatheter aortic valve replacement (TAVR) alters this natural history significantly, providing a 47% reduction in the risk of death over 3 years (HR 0.53, 95% confidence interval 0.41-0.68, p < 0.001). Based upon this demonstration of effective therapy for even surgically inoperable patients, the natural history studies of untreated severe aortic stenosis are complete.
The PARTNER B control arm is not the only group with a concerning outcome: the majority of patients randomized to TAVR are also dead at 3 years follow up. These grim outcomes in both arms of the trial lead to two disturbing questions: 1) Was it necessary to perform a randomized trial in which the control group was already known to have an exceedingly high mortality rate? 2) Were elderly patients with multiple comorbidities unnecessarily included a randomized trial where any active intervention was predestined to be futile?
Randomized Interventional Cardiology Trials and Death
The last two decades of interventional cardiology clinical trials has been dominated by the combined endpoints, surrogate endpoints and goals of non-inferiority. The efficacy of PCI pharmacology is generally defined by peri-procedural elevations in myocardial biomarkers. The impact of coronary stents is demonstrated by either reduction or non-inferiority for a combined endpoint of death, myocardial infarction or target vessel revascularization. Trials of new patients, the natural history studies of untreated severe ao t rtic stenosis are comple lete te. .
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Before we discount the death driven design of PARTNER B, an alternative perspective on death in interventional cardiology trials is warranted: this counterpoint may be best illustrated by comparing the first TAVR trial to the first completed trial of early revascularization for cardiogenic shock. Similar to the challenge faced by the PARTNER investigators, the SHOCK trial investigators knew that patients with acute myocardial infarction complicated by cardiogenic shock had a terminal illness 5 . Rather than look for a combined endpoint or a hemodynamic surrogate, the SHOCK investigators faced the certainty of death with a trial design that answered the essential question in a definitive manner: can we truly alter the natural history of a terminal illness?
There are numerous similarities between these two landmark trials ( urgical risk scores less than 15% to decrease mortality rates in both arms of the study.
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Did SHOCK need a death endpoint or a randomized control group with an expected mortality of 80%? The evidence supporting this design is quite clear from a subsequent story in this field: pathophysiologic observations and hemodynamic endpoint studies suggested that a novel nitric oxide synthase inhibitor, tilarginine, would clearly be superior to standard therapy for patients with acute myocardial infarction complicated by cardiogenic shock 8 . When an international, multicenter mortality driven trial was performed, the surrogate endpoints proved useless and tilarginine had no effect on mortality 9 . Similarly, the superiority of TAVR seems clear retrospectively, but the benefit was much less clear to patients and investigators during the trial: among patients randomized to standard therapy in PARTNER B, all were offered TAVR after the 12 months of initial follow up were completed. Yet, only a minority of patients and clinicians chose the novel therapy: of 58 eligible patients who were alive a 12 months in the standard therapy arm, only 20 patients crossed over to TAVR therapy 10 . Now, we have clarity in both shock and aortic stenosis, and there will never be another control group randomized to medical therapy alone for these disease states. Based upon the history of the SHOCK trial and its Did SHOCK need a death endpoint or a randomized control group with an an n e e exp xp pec e ecte te ted d d mortality of 80%? The evidence supporting this design is quite clear from a subsequent story in r h his is s f f fie ie ield ld ld: : pa pa path t thop p phy hy hysi s ologic observations and he emo mo m d dynamic endp poi o o nt s s stu tu tud dies suggested that a n nov ve vel nitric oxi xide de d s syn ynth tha as ase e e in in nhi h hib bit it tor or or, t ti ila a argin n nin n ne, w w wo o ould d d c cl clea ea arl rl ly y b b be sup upe e eri io or r to to to s sta tand nd nda ar ard d d th h he er erap ap py y y fo or r r pa pa pati ti tien ents ts s w w wit ith h ac c cut ute e e m my myoc ocar ar a di di dial al al i i in nf nfa a arc rc cti ti tion on on c c com om ompl pli ica at ated ed ed b b by y ca ca car rd rdio io oge ge g n n nic c c sh sh hoc oc o k k k 8 8 . . Wh Wh W en en n a a an n nternational, l, m m mul ul lti ti tice ce c nt nt n er e e m m mor or orta a al l lit it ity y dr d d iv iv ven en n t t tri ri r al al a w w was as s p p per erfo fo form rm rmed ed ed, , t t the he h s s sur ur urro ro roga ga gate te t e e end nd ndpo po poin in nts t proved follow up studies, the PARTNER B investigators were right: they had to use a death defined randomized trial design to definitively prove that TAVR alters the natural history of a terminal illness.
Patient Inclusion and Subgroup Analysis
Kapadia et al report a 54% mortality at 3 year follow up of the TAVR arm of PARTNER B 1 .
The authors speculate that this high mortality in the novel treatment arm "highlights the need for better case selection, especially in those with multiple co-morbidities". Support for this concept comes from subgroup analysis demonstrating the interaction of TAVR effectiveness with baseline assessment of surgical risk. When patients are stratified according to 3 tertiles of STS scores, the greatest absolute reduction in all-cause mortality (67%) is in the lowest STS (estimated risk < 5.0%) group with a much less impressive absolute reductions in mortality (21%) among patients with STS scores over 15%. Thus, it is tempting to conclude that our selection process for TAVR extreme risk patients should begin with the STS score; elderly patients with STS scores over 15% may represent the cohort C of the PARTNER trials-the group which should never have been randomized in PARTNER A or B trials due to futility of any aggressive therapy. Other risk scores have similarly been calculated to help guide clinicians with better selection of patients for TAVR 11 .
Once again, the SHOCK trial may provide an alternative perspective on this conclusion.
Like PARTNER, SHOCK had prespecified subgroup analyses, generally intended to determine the consistency of a novel treatment effect. In SHOCK, there was a glaring inconsistency: among patients over age 75, the benefit of an early revascularization approach was not seen 5 . In fact, there was a 41% increased risk of death among elderly patients undergoing early revascularization as compared to intensive medical therapy (p=0.01). This subgroup analysis cores, the greatest absolute reduction in all-cause mortality (67%) is in the lowes es st ST ST STS S S estimated risk < 5.0%) group with a much less impressive absolute reductions in mortality 2 21% 1% %) ) ) am am amon on ong g g pa a ati ti tie en ents with STS scores over 15% %. %. T T Thus, it is tem mpt pt p ing g to to to conclude that our e ele e ect c ion proc ces ess s s f f for r TA TA TAVR VR VR e ex xt xtre reme me me r ris isk k pa a atie e ents s s sh hou ul uld d d be be eg gi in n w wi with th t th h he ST STS S S sc scor or re; e; e e eld ld lder r rly l ly pa pati ti tien en nts ts t w wit it ith h h ST STS S sc scor ores es s o ove e er r r 15 15 15% % % ma ma may y y re re repr pr pres es sen en e t t t th th he co co oho ho hor rt C C C o o of th th the e e PA PA PART RT TNE NE NER R tr tr ri i ials s s--t -the he e group which h sh sh shou ou ould ld ld n nev ev ever h h hav av ave e be be been en n ran an ando do domi mi mize ze zed d had an impact: initial guideline statements restricted the Class I recommendation for early revascularization in the setting of shock to only those patients who were not elderly 7 . The scope of this restricted recommendation was not small: like aortic stenosis, cardiogenic shock is a disease of the elderly and older age is the strongest predictor of shock complicating acute myocardial infarction. Thus, withholding the SHOCK early revascularization strategy among elderly patients could eliminate nearly 40% of affected patients with the disease from qualifying for the only proven therapy to impact mortality 12 . If one looks carefully at the SHOCK elderly subgroup analysis, caution is clearly warranted: there were only 56 randomized elderly patients in the SHOCK trial and thus any conclusions from this subgroup analysis are necessarily ambiguous. Furthermore, subsequent large registry studies failed to demonstrate any clear harm of early revascularization (and suggested potential benefit) in the elderly shock patient thus calling into question a restricted guideline and pointing towards clinical judgement rather than subgroup analysis as a means of patient selection [12] [13] [14] .
The analogy with PARTNER reminds us to go slow in applying the findings of subgroup analysis to our clinical practice: while improved selection of patients for TAVR is clearly warranted, the temptation to exclude any single subgroup based upon the PARTNER B analysis should be avoided. Like SHOCK, randomizing approximately 350 patients means that each subgroup of the novel treatment group consisted of a small number of patients. Only 104 patients in PARTNER B had an STS score over 11 and at three year follow up, the p value for interaction between STS score and mortality was strikingly non-significant (p=0.74) 1 : similar to the 56 elderly patients in SHOCK, this small sample size makes it hard to be certain of the futility of TAVR in higher STS score patients. While we may be concerned with application of TAVR to elderly patients in whom it may be futile, the European experience suggests that the ambiguous. Furthermore, subsequent large registry studies failed to demonstrate e an an any y y cl cl clea a ear r r ha ha harm rm of early revascularization (and suggested potential benefit) in the elderly shock patient thus ca all ll lin in ing g g i in into to tou uest st tio io ion n a restricted guideline and po po poin int ting towards c cli l l nica ca al l l j ju judgement rather than u ubg bg group analy lysi si s s as s a a a m m mea ea ean n ns s s o of of p p pat at atie ien n nt sele e ect t tion 12-12-14 .
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Conclusion
The 3 year follow up of PARTNER B is a disturbing final reminder of the natural history of severe aortic stenosis. Even with the implementation of an exciting new technology, we are still facing death: in this extreme risk population, the majority of TAVR patients will be dead at 3
years. In the face of so much death, we are indebted to the PARTNER investigators for providing us with a definitive trial design that makes a final statement: the conclusions of PARTNER B, like SHOCK, require no further proof in subsequent trials. These conclusions from the 358 patients in PARTNER B (and the subsequent continued access study) are both narrow and powerful: TAVR saves lives in extreme risk patients with severe symptomatic aortic stenosis.
Due to PARTNER B, we have a good therapy for a patient group at extreme risk for death and we have hypotheses to generate the future clinical trials focusing on improving selection, pharmacology and technology to guide our therapy 16, 17 . facing death: in this extreme risk population, the majority of TAVR patients wi ill ll l b be e e de de dead ad ad a a at t t 3 3
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